Results 141 to 150 of about 1,042 (177)

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.

JAMA Dermatol
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG, OLYMPIA 1 Investigators.   +26 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nemolizumab for atopic dermatitis

Drugs of Today, 2022
Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus.
Angelina, Labib, Ashley, Vander Does, Gil, Yosipovitch   +2 more
openaire   +2 more sources

Nemolizumab: First Approval

Drugs, 2022
Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic
openaire   +2 more sources

Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis

Journal of Drugs in Dermatology, 2023
Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical trial results were combined with population PK (popPK) and pharmacokinetic/ pharmacodynamic (PK/PD) models to optimize nemolizumab dosing.
Nathalie, Wagner, Luca, Loprete, Vincent, Duval, Petra, Jauslin, Khaled, Benkali, Jonathan I, Silverberg, Andreas, Wollenberg, Tomohisa, Saito, Faiz, Ahmad, Michael, Graeber, Warren, Winkelman, Christophe, Piketty   +11 more
openaire   +2 more sources

Perforating dermatosis in a patient on haemodialysis successfully treated with nemolizumab

Clinical and Experimental Dermatology, 2023
We present a case of perforating dermatosis in a patient with uraemic pruritus who was on haemodialysis and who was successfully treated with nemolizumab, a humanized monoclonal antibody targeted against interleukin-31 receptor A. Nemolizumab may be a treatment option for perforating dermatosis with a uraemic pruritus background. To our knowledge, this
Shun, Ohmori, Yu, Sawada
openaire   +2 more sources

A critical evaluation of nemolizumab for prurigo nodularis

Expert Review of Clinical Immunology
Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with intensely pruritic, hyperkeratotic nodules. The pathophysiology underlying PN is not entirely clear, making treatment challenging. Patients often require a multimodal approach, although many of the available therapies have low efficacy or adverse effects.In this review ...
Sarah G, Brooks, Gil, Yosipovitch
openaire   +2 more sources

Nemolizumab (Nemluvio) for Atopic Dermatitis

The Medical Letter on Drugs and Therapeutics
Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical ...
openaire   +2 more sources